Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Fourth COVID Shots for Older Adults and High-Risk People: LDP Project Team
Lawmakers of the ruling Liberal Democratic Party (LDP) appear to see the need for a second COVID-19 booster for older adults and people with high risks of developing severe diseases, but not necessarily for all residents who received three doses.…
To read the full story
Related Article
- LDP Adopts Proposal on 4th COVID-19 Vaccination, Urges Govt to Ponder Cost-Effectiveness
April 20, 2022
- Secure New mRNA Jabs, 4th Shots for Older Adults and People with Medical Conditions: LDP
April 18, 2022
- Moderna, Daiichi Sankyo Give mRNA Vaccine Updates: LDP Meeting
April 7, 2022
- MHLW Urges Prefectural Govts to Prep for 4th COVID Shot over Next 2 Months
March 28, 2022
- LDP Project Team to Discuss Fourth COVID Shot
March 17, 2022
REGULATORY
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026
- LDP Lawmakers’ League Urges Economic Efficiency in Drug Use
May 27, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…